Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
Hanna TukachinskyRussell W MadisonJon H ChungOle V GjoerupEric A SeversonLucas DennisBernard J FendlerSamantha MorleyLei ZhongRyon P GrafJeffery S RossBrian M AlexanderWassim AbidaSimon ChowdhuryCharles J RyanKarim FizaziTony GolsorkhiSimon P WatkinsAndrew D SimmonsAndrea LoehrJeffrey M VenstromGeoffrey R OxnardPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Genomic analysis of ctDNA from patients with mCRPC recapitulates the genomic landscape detected in tissue biopsies, with a high level of agreement in detection of BRCA1/2 mutations, but more acquired resistance alterations detected in ctDNA. CGP of ctDNA is a compelling clinical complement to tissue CGP, with reflex to tissue CGP if negative for actionable variants.See related commentary by Hawkey and Armstrong, p. 2961.